Brand Reference: Benicar
| Metric | Verified Benchmark | Source |
|---|---|---|
| Olmesartan Medoxomil RxNorm Concept ID | 321064 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0980 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $84.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $6.80 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $8.50 / mo | 14 Zero-PHI Verified Patient Logs |
De-esterified during gastrointestinal mucosal absorption into active olmesartan, tightly binding vascular smooth-muscle AT1 receptors via double-chain carboxyl/hydroxyl interaction for high-amplitude systolic blood pressure reduction.
CMS National Average Drug Acquisition Cost (NADAC) tracking places Olmesartan Medoxomil (Benicar, RxCUI 321064) at $0.0980 per unit, whereas walk-in chain pharmacies bill cash patients an average of $84.00 monthly—creating a 92% ($77.20/mo) wholesale arbitrage spread down to $6.80.
Systemic exposure to Olmesartan Medoxomil reflects 26% oral absorption kinetics and complete ester hydrolysis during absorption; zero cyp450 metabolism; 40% renal / 60% biliary, sustaining receptor engagement across a 13 hours half-life window (1–2 weeks near-maximal bp control response profile).
Dosing protocols (20 mg PO once daily or 40 mg PO once daily) balance efficacy (86.40% patient satisfaction across 14 logs) against dizziness (7% of reports), chronic diarrhea (rare sprue screen) (3% of reports), with strict avoidance in pregnancy; sprue-like enteropathy history on olmesartan.
Across 14 verified cash-pay logs, Olmesartan Medoxomil achieves a 86.40% Worth-It rating with out-of-pocket spend averaging $8.50/mo versus $84.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 20 mg PO once daily for Olmesartan Medoxomil; monthly out-of-pocket dropped to $5.98 compared with $84.00 retail.
Completed 10 weeks on Olmesartan Medoxomil (40 mg PO once daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 20 mg PO once daily Olmesartan Medoxomil sourced via TeleMed ($7.89/mo cash pay without insurance prior authorization).